Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results
Authors' conclusion
There was no difference between ODT and standard ticagrelor tablets in terms of post-LD residual platelet reactivity, percentage of platelet inhibition or safety regardless to morphine use.
Study context
- Population
- Patients with STEMI or very high-risk NSTE-ACS undergoing percutaneous coronary intervention (PCI), by morphine userandomised
- Participants
- One-hundred and 30 patients
- Comparison
- Orodispersible ticagrelor vs standard coated tablet ticagrelor 180 mg loading dose (LD)
- Primary endpoint
- Residual platelet reactivity (PRU, VerifyNow) across the two ticagrelor formulations and by morphine use
- Follow-up
- 1 h after LD
Methodological detailsstratified randomisation by morphine use
- Stratified randomisation by morphine use
Primary result
As reported in the abstract
1-h PRU, by morphine use
Further findings
1-h PRU, morphine vs no morphine · 1 h after LD · morphine n = 32; no morphine n = 98
P = 0.012
Platelet reactivity at 2, 4 and 6 h · 2, 4 and 6 h after LD
- Similar in the 2 study arms
Safety
In-hospital adverse events or drug side-effects, with vs without morphine
- Reinfarction due to acute stent thrombosis in a morphine-treated patient
- 1
- No significant difference
Original publication
Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results. Eur Heart J Cardiovasc Pharmacother. Published 17 August 2023. doi:10.
Summarised from the published abstract; every number is checked against it